For 5 patients, IHC-staining in immune cells was not clearly detectable; of the 117 remaining patients, corresponding to 248 evaluable tumor specimens, tumor immune infiltrate was IDO-1 negative in 63 patients (53.8%), while in 54 patients (46.2%) tumor immune infiltrate was IDO-1 positive, in particular with a percentage of IDO-1+ immune cell between 1 and 25; there were no patients with a percentage higher than 25% (Figure 2). Here, IDO1 is linked to neoplasm.